OKYO · OKYO Pharma Limited

Summary

OKYO Pharma Limited announced that Non-Executive Director John Brancaccio acquired 5,000 ordinary shares on NASDAQ at $1.61, bringing his total holding to 31,201 shares. The company is a clinical-stage biopharmaceutical developing therapies for neuropathic corneal pain and inflammatory eye diseases.

Key takeaways

• John Brancaccio, Non-Executive Director, acquired 5,000 ordinary shares at $1.61
• Post-acquisition total holding: 31,201 shares